---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-26-004910"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2026-05-14T21:16:25+00:00"
generated_at: "2026-05-14T21:18:09.098102+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI enters 50/50 revenue-sharing partnership with Amarox for Multikine in Saudi Arabia

## Summary
- 50%/50% net revenue share for Multikine sales in Saudi Arabia; Amarox exclusive distributor upon SFDA approval.
- Amarox ranked #1 for SFDA critical/unavailable medicine applications for 3 consecutive years (2022-2024).
- Optional extension to GCC countries (Bahrain, Kuwait, Oman, Qatar, UAE). CEL-SCI retains all IP and global rights.
- Partnership targets SFDA Breakthrough Medicine Designation for Multikine in head and neck cancer.

## SEC filing metadata
- accession: 0001654954-26-004910
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2026-05-14T21:16:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495426004910/0001654954-26-004910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495426004910/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-26-004910
- JSON: https://secwatch.observer/filing/0001654954-26-004910.json
- Plain text: https://secwatch.observer/filing/0001654954-26-004910.txt

## Key facts
- Material Agreements
  CEL SCI CORP entered into a license with Amarox.
  - Action: entry
  - Agreement: license
  - Counterparty: Amarox
  source text: the Company issued a press release, filed as Exhibit 99, concerning a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in Saudi Arabia, with an optional extension for the Gulf Cooperation Council (GCC) countries including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/725363/000165495426004910/0001654954-26-004910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.